Immutep Limited announced that it has entered into a clinical trial collaboration agreement, a supply agreement and a service agreement with CYTLIMIC Inc. for its lead product candidate eftilagimod alpha as part of a cancer vaccine. The agreements enable the two parties to collaborate on clinical trials to evaluate efti as part of a therapeutic cancer vaccine (a therapy containing cancer antigens to boost a patient's own immune cells to recognize and kill cancer cells related to the antigens) containing CYTLIMIC's innovative cancer peptide vaccine, called CYT001. The trials will be conducted by and are under the control of CYTLIMIC who will fully fund all development costs. Under the collaboration agreement, Immutep will receive an upfront payment of USD 500,000 and is eligible to receive up to USD 4.5 million in milestone payments upon the achievement of milestones by CYTLIMIC. In addition to the collaboration agreement, Immutep has entered into a supply agreement to provide efti to CYTLIMIC for the manufacture of CYT001 for use in the clinical development and commercialisation of the vaccine. The Parties have also entered into a service agreement where Immutep will provide technical support services to CYTLIMIC during the development and commercialisation of CYT001.